Supernus Pharmaceuticals, Inc.
SUPN
$50.53
$1.162.35%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -1.83% | 10.13% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -1.83% | 10.13% | |||
| Cost of Revenue | 23.60% | 5.18% | |||
| Gross Profit | -9.87% | 11.80% | |||
| SG&A Expenses | 1.80% | 12.14% | |||
| Depreciation & Amortization | 4.56% | 0.83% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.68% | 8.81% | |||
| Operating Income | -163.20% | 38.91% | |||
| Income Before Tax | -210.87% | 96.70% | |||
| Income Tax Expenses | -266.91% | 117.07% | |||
| Earnings from Continuing Operations | 44.14% | 90.90% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 44.14% | 90.90% | |||
| EBIT | -163.20% | 38.91% | |||
| EBITDA | -49.19% | 10.54% | |||
| EPS Basic | 44.41% | 91.03% | |||
| Normalized Basic EPS | -135.33% | 30.56% | |||
| EPS Diluted | 44.67% | 90.96% | |||
| Normalized Diluted EPS | -135.33% | 30.56% | |||
| Average Basic Shares Outstanding | 0.53% | 1.40% | |||
| Average Diluted Shares Outstanding | 0.53% | 1.40% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||